NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD
Post# of 85
PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. “The Ministry of Health (‘MOH’) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica’s dedication to mitigating the devastating impact of sleeping sickness and ensuring access to life-saving medications in regions facing critical shortages,” a recent article reads. “This recent development follows PaxMedica’s completion of three pivotal registration/validation batches of PAX-101, marking a significant milestone in the company’s ongoing development program. PaxMedica’s collaborative efforts with physicians and government bodies in Malawi and neighboring countries further demonstrate its commitment to advancing treatments for Trypanosoma brucei rhodesiense Human African trypanosomiasis (‘TBr HAT’).”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer